Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease

Topic: Disease mechanisms in lab and animal studies

Introduction Pathologically modified tau protein is the main feature of Alzheimer's disease (AD) and related tauopathies. Therefore, immunotherapies that target mis-disordered tau represent a promising avenue for the disease-modifying treatment of AD. In this report, we present our discovery of (1) a novel target for tau immunotherapy; (2) monoclonal antibody DC8E8, which neutralizes this target; and (3) the results of efficacy studies of DC8E8 in a murine model of tauopathy. Methods In vitro tau oligomerisation assays were used for the selection of antibodies. The therapeutic efficacy of DC8E8 was evaluated in transgenic mice. The structure of the DC8E8 epitope was determined by X-ray crystallography. Results Screening of a panel of monoclonal antibodies for their inhibitory activity in an in vitro pathological tau-tau interaction assay yielded DC8E8, which reduced the amount of oligomeric tau by 84%. DC8E8 recognised all developmental stages of tau pathology in AD human brains, including pretangles and intra- and extracellular tangles. Treatment with DC8E8 in a mouse AD model expressing mis-disordered human tau significantly reduced the amount of insoluble oligomerised tau and the number of early and mature neurofibrillary tangles in the transgenic mouse brains. By using a panel of tau-derived peptides in a competitive enzyme-linked immunosorbent assay, we identified the tau domain essential for pathological tau-tau interaction, which is targeted by DC8E8. The antibody was capable of binding to four highly homologous and yet independent binding regions on tau, each of which is a separate epitope. The X-ray structure of the DC8E8 Fab apo form, solved at 3.0 Å, suggested that the four DC8E8 epitopes form protruding structures on the tau molecule. Finally, by kinetic measurements with surface plasmon resonance, we determined that antibody DC8E8 is highly discriminatory between pathological and physiological tau. Conclusions We have discovered defined determinants on mis-disordered truncated tau protein which are responsible for tau oligomerisation leading to neurofibrillary degeneration. Antibody DC8E8 reactive with these determinants is able to inhibit tau-tau interaction in vitro and in vivo. DC8E8 is able to discriminate between the healthy and diseased tau proteome, making its epitopes suitable targets, and DC8E8 a suitable candidate molecule, for AD immunotherapy.

Key findings

• In this report, we present our discovery of (1) a novel target for tau immunotherapy; (2) monoclonal antibody DC8E8, which neutralizes this target; and (3) the results of efficacy studies of DC8E8 in a murine model of tauopathy.
• Results Screening of a panel of monoclonal antibodies for their inhibitory activity in an in vitro pathological tau-tau interaction assay yielded DC8E8, which reduced the amount of oligomeric tau by 84%.
• Treatment with DC8E8 in a mouse AD model expressing mis-disordered human tau significantly reduced the amount of insoluble oligomerised tau and the number of early and mature neurofibrillary tangles in the transgenic mouse brains.
• The X-ray structure of the DC8E8 Fab apo form, solved at 3.0 Å, suggested that the four DC8E8 epitopes form protruding structures on the tau molecule.

New to this subject? Start with our plain-English guide: Treatments →

Study details

• Evidence strengthLow

Read the original

• DOI: 10.1186/alzrt277
• PubMed: 25478018
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{kontsekova2014-25478018,
  author  = {Kontsekova, E. and Zilka, N. and Kovacech, B. and Skrabana, R. and Novak, M.},
  title   = {{Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2014},
  doi     = {10.1186/alzrt277},
  pmid    = {25478018},
  url     = {https://doi.org/10.1186/alzrt277}
}

Related studies in Drug development

• Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein The Biochemical journal · 1994-08-01 · usefulness score 36/100
• Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015-03-01 · usefulness score 36/100
• Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules Lipids in health and disease · 2008-10-15 · usefulness score 40/100
• Evaluation of [18F]MK-6240 binding to tau protein in postmortem human brains of Down syndrome and Alzheimer’s disease and assessment of off-target (non-tau) binding Research Square · 2026-01-06 · usefulness score 16/100
• From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy Acta neuropathologica · 2019-11-04 · usefulness score 45/100
• Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach Current Alzheimer research · 2012-05-01 · usefulness score 36/100

Also tagged “phosphorylation”

387 studies in the library carry the topic tag “phosphorylation”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 387 tagged studies.

• YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies Journal of Neuroinflammation · 2017-06-09 · usefulness score 41/100 · Biomarkers
• Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial Lancet (London, England) · 2016-11-16 · usefulness score 79/100 · Drug development
• Roles of tau protein in health and disease Acta neuropathologica · 2017-04-06 · usefulness score 43/100 · Disease mechanisms

Similar studies

• Molecular Insights into Tau Pathology and its Therapeutic Strategies in Alzheimer's Disease 2024 · Drug development
• Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau 2018 · Drug development
• Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody 2019 · Drug development
• Tau-targeting therapies for Alzheimer disease 2018 · Drug development
• Tau immunotherapy for Alzheimer's disease 2015 · Drug development
• "Tau immunotherapy: Hopes and hindrances" 2018 · Drug development

More on Drug development

• A review that covers this ground GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease Reviews in the neurosciences · 2011-12-21 · usefulness score 36/100
• Newest in this subject The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration Metabolism: clinical and experimental · 2026-10-30 · Peer-reviewed · usefulness score 45/100
• Newest in this subject Effect of Metformin on tau pathology and proteostasis in cellular and a Drosophila model of Tauopathy Research Square · 2026-10-29 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Drug development →